Serina Therapeutics Q4 EPS $(0.31) Beats $(0.46) Estimate

Serina Therapeutics reported a Q4 EPS of $(0.31), surpassing the analyst estimate of $(0.46) by 32.61%. This represents a 29.17% increase in losses compared to $(0.24) per share in the same quarter last year.